Ugur Sahin

$3.91 B

Ranked #1058 in World

About Ugur Sahin

Hailing from İskenderun, Turkey (1965), a foremost physician-scientist made Germany his home at a young age, advancing his expertise at the University of Cologne and Fernuniversität Hagen in medicine and mathematics. Esteemed for his role in oncology and mRNA vaccine development, including the pivotal BNT162b2 against COVID-19, his merits extend from co-founding Ganymed Pharmaceuticals and BioNTech to distinguished memberships and accolades in medical science innovation.

Born

September 19, 1965 in Iskenderun, Hatay Province, Turkey

Age

60 years

Source Of Wealth

Biotechnology

Industries

Healthcare

Citizenship

Germany

Residence

Mainz

Spouse

Ozlem Tureci (Married: 2002)

Children

Uğur Şahin was born on September 19, 1965, in İskenderun, Turkey. At the age of four, he moved to Germany with his mother to join his father in Cologne.

Ugur Sahin: Family

Uğur Şahin is married to Özlem Türeci, who is also a physician and scientist. They have two children together.

Ugur Sahin: Career Highlights

Uğur Şahin's career highlights include:

Working as a physician in internal medicine and hematology/oncology from 1991 to 2000 at the University Hospital of Cologne and the Saarland University Hospital in Homburg.
Habilitating in 1999 in the field of molecular medicine and immunology.
Joining Christoph Huber at the University Medical Center Mainz in 2000.
Becoming a professor for experimental oncology at the Department for Internal Medicine/Oncohematology in 2006.
Co-founding the company Ganymed Pharmaceuticals in 2001 with his wife Özlem Türeci and his mentor Christoph Huber.
Co-founding the biotechnology company BioNTech in 2008 with Özlem Türeci and Christoph Huber.
Serving as the CEO of BioNTech.
Leading the development of the BNT162b2 mRNA vaccine against COVID-19.

Ugur Sahin: Companies

Uğur Şahin has co-founded two companies:

Ganymed Pharmaceuticals (2001)
BioNTech (2008)

Ugur Sahin: Major Achievements

Uğur Şahin's major achievements include:

Developing strategies that allow different layers of mRNA vaccine optimization.
Pioneering mRNA vaccines for personalized cancer therapy that are based on non-nucleoside modified mRNA.
Developing RNA vaccine nanoparticle delivery strategies that target tissue-derived dendritic cells body-wide.
Developing ways to use RNA vaccine technology for in vivo expansion and enhanced engraftment of genetically engineered, adoptively transferred CAR-T cells.
Developing a novel therapeutic strategy that circumvents systemic immunosuppression by inhibiting only the immune cells that mediate autoimmune disease.
Leading the development of the BNT162b2 mRNA vaccine against COVID-19.

Ugur Sahin: Awards & Achievements

Uğur Şahin has received numerous awards and achievements, including:

Vincenz Czerny Prize of the German Society of Hematology and Oncology (DGHO) (1995)
Merit Award of the American Society of Clinical Oncology (ASCO) (1995)
Calogero Paglierello Research Award (1997)
Georges Köhler Prize of the German Society of Immunology (2005)
GO-Bio Prize of the Federal Ministry of Education and Research (2006 and 2010)
BMBF Spitzencluster Award for TRON projects as part of CI3-Regional Cluster for Individualized Immune Intervention (2012)
ERC Advanced Grant in Life Sciences (2017/18)
Mustafa Prize (2019)
German Cancer Award (2019)
The National German Sustainability Award (2020)
Financial Times Person of the Year (2020)
Knight Commander's Cross of the Order of Merit of the Federal Republic of Germany (2021)
Hall of Fame German Science (2021)
Empress Theophano Prize (2021)
Election as a Member of EMBO (2021)
Karl Heinz Beckurts Prize (2021)
Princess of Asturias Award in the category "Scientific Research" (2021)
William B.
Coley Award (2021)
SITC Medal of Honor (2021)
German Future Prize (2021)
Empress Theophano Prize (2021)
Paul Ehrlich and Ludwig Darmstaedter Prize (2022)
Honorary doctorate of the Philipps University of Marburg (2022)
Honorary doctorate from the Universiteit van Amsterdam (2022)
Louis-Jeantet Prize (2022)
Werner-von-Siemens-Ring (2022)
Order of Merit of the State of Rhineland-Palatinate (2022)
Ring of Honor of the University Medicine Mainz (2022)
Honorary citizenship of Mainz (2022)
Novo Nordisk Prize (2022)
Warren Alpert Foundation Prize (2022)
Pour le Mérite (2023)

Ugur Sahin: Personal Life & Legacy

Uğur Şahin is married to Özlem Türeci, who is also a physician and scientist. They have two children together. Şahin is a Muslim.

Ugur Sahin: Trivia

Uğur Şahin is a fan of the Turkish football club Galatasaray S.K.

Wealth History

Timeline

19 September 1965

Born in İskenderun, Turkey.

1969

Moved to Germany with his mother to join his father in Cologne.

1984

Started studying medicine at the University of Cologne.

1991

Began working as a physician in internal medicine and hematology/oncology at the University Hospital of Cologne.

1992

Received his doctorate in medicine with a thesis on immunotherapy against tumor cells.

1992

Started studying mathematics at the Fernuniversität Hagen.

1994

Completed his studies in mathematics.

1995

Received the Vincenz Czerny Prize of the German Society of Hematology and Oncology (DGHO).

1995

Received the Merit Award of the American Society of Clinical Oncology (ASCO).

1997

Received the Calogero Paglierello Research Award.

1999

Habilitated in the field of molecular medicine and immunology.

2000

Joined Christoph Huber at the University Medical Center Mainz.

2001

Co-founded the company Ganymed Pharmaceuticals with his wife Özlem Türeci and his mentor Christoph Huber.

2004

Became a member of the German Society of Immunology.

2005

Received the Georges Köhler Prize of the German Society of Immunology.

2006

Received the GO-Bio Prize of the Federal Ministry of Education and Research.

2006

Became a professor for experimental oncology at the Department for Internal Medicine/Oncohematology.

2008

Co-founded the biotechnology company BioNTech with Özlem Türeci and Christoph Huber.

2008

Became a member of the Program Committee of the Association for Cancer Immunotherapy (CIMT), Regulatory Research Group, Mainz.

2010

Received the GO-Bio Prize of the Federal Ministry of Education and Research.

2012

Co-founded the Cluster of Individualized Immunointervention (CI3) in Mainz.

2012

Received the BMBF Spitzencluster Award for TRON projects as part of CI3-Regional Cluster for Individualized Immune Intervention.

2014

Became a member of the American Association for Cancer Research (AACR).

2015

Became a member of the American Society of Clinical Oncology (ASCO).

2017

Received an ERC Advanced Grant in Life Sciences.

2019

Received the Mustafa Prize.

2019

Received the German Cancer Award.

2020

Received the National German Sustainability Award.

2020

Named Financial Times Person of the Year.

2021

Elected as a member of the European Molecular Biology Organization (EMBO).

2021

Received the Knight Commander's Cross of the Order of Merit of the Federal Republic of Germany.

2021

Inducted into the Hall of Fame German Science.

2021

Received the Empress Theophano Prize.

2021

Received the Karl Heinz Beckurts Prize.

2021

Received the Princess of Asturias Award in the category "Scientific Research".

2021

Received the William B. Coley Award.

2021

Received the SITC Medal of Honor.

2021

Received the German Future Prize.

2021

Received the Empress Theophano Prize.

2022

Received the Paul Ehrlich and Ludwig Darmstaedter Prize.

2022

Awarded an honorary doctorate from the Philipps University of Marburg.

2022

Awarded an honorary doctorate from the Universiteit van Amsterdam.

2022

Received the Louis-Jeantet Prize.

2022

Received the Werner-von-Siemens-Ring.

2022

Awarded the Order of Merit of the State of Rhineland-Palatinate.

2022

Received the Ring of Honor of the University Medicine Mainz.

2022

Granted honorary citizenship of Mainz.

2022

Received the Novo Nordisk Prize.

2022

Received the Warren Alpert Foundation Prize.

2023

Awarded the Pour le Mérite.

Ugur Sahin : FAQs

What is Ugur Sahin's current net worth?

Ugur Sahin's current net worth is $3.91 billion.

What is Ugur Sahin's current global rank among billionaires?

Ugur Sahin holds the 1058th position globally among billionaires.

What is Ugur Sahin's current ranking within the Germany?

Ugur Sahin holds the 70th position in Germany.

What was the change in Ugur Sahin's net worth compared to the previous year?

Ugur Sahin's net worth decreased by 150.67 million dollars compared to the previous year 2025, when his net worth was 4.06 billion dollars.

What are Ugur Sahin's main sources of wealth?

Ugur Sahin's main source of income comes from Biotechnology.

In which industry does Ugur Sahin primarily operate?

Ugur Sahin is primarily involved in the Healthcare industry.

How old is Ugur Sahin?

Ugur Sahin is 60 years old.

Who was born on 19 September 1965 in İskenderun, Turkey, and later became a renowned scientist?

The individual born on 19 September 1965 in İskenderun, Turkey, is a distinguished scientist who studied medicine and later co-founded BioNTech, leading the development of the BNT162b2 mRNA vaccine against COVID-19.

What academic path did the co-founder of BioNTech follow before becoming CEO?

The co-founder of BioNTech pursued medicine at the University of Cologne, completed his doctorate in immunotherapy for cancer cells, and studied mathematics at Fernuniversität Hagen, sealing his expertise before ascending to the CEO role at BioNTech.

How did the founder of Ganymed Pharmaceuticals contribute to cancer research and vaccine development?

The founder of Ganymed Pharmaceuticals has made significant contributions to cancer research by identifying new target molecules for immunotherapy, developing mRNA vaccines and RNA as therapeutic strategies, before pivoting to pioneer the COVID-19 vaccine with BioNTech.

Which organizations and societies has the current CEO of BioNTech been involved with since 2004?

The CEO of BioNTech has been a member of various prestigious organizations, including the German Society of Immunology, AACR, ASCO, and EMBO, reflecting a deep commitment to advancing cancer research and immunology.

Can you list some of the major awards received by the scientist who led the development of the BNT162b2 mRNA vaccine?

The scientist behind the BNT162b2 mRNA vaccine has been honored with multiple accolades, such as the German Cancer Award, Knight Commander's Cross of the Order of Merit of the Federal Republic of Germany, and the prestigious Princess of Asturias Award in Scientific Research, acknowledging his groundbreaking work in science and medicine.